Last updated: 2026-10-12 14:59:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Genelux Corporation (GNLX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.52, with a market capitalization of $115.83M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.29 to $8.54. This page covers its latest market performance, valuation, price trends and company information.
$115.83M | |
$2.59 | |
$40.98 | |
$1.60 | |
$2.56 | |
8.49K | |
276.28K | |
-- | |
$8.54 | |
$2.29 | |
-- | |
-- |
Genelux Corporation (GNLX) is currently trading at $2.52 as of 2026-10-12 14:57:00, down 1.76% ($0.04) from the previous close of $2.56
During today's regular trading session, GNLX has traded between $1.60 and $40.98, with a trading volume of 8.49K shares. The current price is near the lower end of today's range.
Over the past seven days, Genelux Corporation (GNLX) moved from $2.52 to $2.52, representing a decline of 0.20% ($0.00).
The stock traded between $2.42 and $2.66 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 262.70 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3.6%
GNLX is currently trading at $2.52, placing it 3.6% of the way from its 52-week low of $2.29 to its 52-week high of $8.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 26 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Genelux Corporation (GNLX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.